pc ¹öÀüÀ¸·Î À̵¿ Áß [½ÃÀ庸°í¼­]¼¼°èÀÇ CAR-T ¼¼Æ÷ Ä¡·á - ½ÃÀå ±Ô¸ð, ¿¹Ãø, ½ÃÇè, µ¿Çâ(2025³â)
¼¼°èÀÇ CAR-T ¼¼Æ÷ Ä¡·á - ½ÃÀå ±Ô¸ð, ¿¹Ãø, ½ÃÇè, µ¿Çâ(2025³â)
Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends, 2025
»óÇ°ÄÚµå : 1657662
¸®¼­Ä¡»ç : BioInformant Worldwide LLC
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 333 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,197 £Ü 6,206,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,797 £Ü 7,093,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,197 £Ü 7,684,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ±ÔÁ¦ ½ÂÀÎ

2017³â ÀÌÈÄ 13°³ÀÇ CAR-T ¼¼Æ÷ Ä¡·á°¡ ¿©·¯ ÀÇ·á ½ÃÀå¿¡¼­ »ó¾÷È­¿¡ À̸£°í ÀÖ½À´Ï´Ù. 7°¡Áö Ä¡·á¹ýÀÌ ¹Ì±¹ FDA¿¡ ÀÇÇØ ½ÂÀÎµÈ ÈÄ, ´Ù¸¥ ÁÖ¿ä ÀÇ·á ½ÃÀå¿¡¼­µµ ½ÂÀÎÀÌ ¹ßÇàµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ý¿¡´Â ´ÙÀ½ÀÌ Æ÷ÇԵ˴ϴÙ.

  • 1. Kymriah(tisagenlecleucel)
  • 2. Yescarta(axicabtagene ciloleucel)
  • 3. Tecartus(brexucabtagene autoleucel)
  • 4. Breyanzi(lisocabtagene maraleucel)
  • 5. Abecma(idecabtagene vicleucel)
  • 6. Carvykti(ciltacabtagene autoleucel)
  • 7. Aucatzyl(obecabtagene autoleucel)

¹Ì±¹ ¹Û¿¡¼­´Â Áß±¹ÀÇ NMPA¿¡¼­ Relma-cel, Fucaso, Yuanruida ¹× Zever-celÀÇ 4°¡Áö CAR-T Ä¡·áÀÌ ½ÂÀεǾú½À´Ï´Ù. ¶ÇÇÑ NexCAR19¿Í QartemiÀÇ µÎ °¡Áö Ä¡·á¹ýÀÌ Àεµ CDSCO·ÎºÎÅÍ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù.

½ÃÀå È®´ë¿Í »ê¾÷ ¼ºÀå

ÀÌ ±ÔÁ¦ ½ÂÀÎÀº Å« °íºñÀ̸ç CAR-T ½ÃÀåÀº »ý¸í °øÇп¡¼­ ¿ìÀ§¸¦ È®¸³ÇÕ´Ï´Ù. M&A´Â ƯÈ÷ Àû±ØÀûÀ̸ç ÅõÀÚÀÚÀÇ °­ÇÑ ½Å·Ú°¨À» º¸¿©ÁÝ´Ï´Ù. Celgene¿¡ ÀÇÇÑ Juno TherapeuticsÀÇ 90¾ï ´Þ·¯ Àμö´Â ÀÌ »ê¾÷ÀÇ ÀáÀç·ÂÀ» µ¸º¸ÀÌ°Ô ÇÏ°í, À̾î Bristol-Myers Squibb(BMS)°¡ CelgeneÀ» 740¾ï ´Þ·¯·Î ÀμöÇß½À´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿òÁ÷ÀÓÀº ±æ·¹µå°¡ Å°Æ® Æĸ¶¸¦ 119¾ï ´Þ·¯·Î ÀμöÇÏ¿© ÀÌ ºÐ¾ßÀÇ ÀÔÁö¸¦ ´õ¿í °­È­Çß´Ù´Â Á¡ÀÔ´Ï´Ù. ¶ÇÇÑ Astellas Pharma´Â Xyphos Biosciences¸¦ 6¾ï 6,500¸¸ ´Þ·¯¿¡ ÀμöÇÏ¿© Æ÷Æ®Æú¸®¿À¸¦ È®´ëÇß½À´Ï´Ù. ÀÌ·¯ÇÑ °Å·¡´Â ÁÖ¿ä Á¦¾à ±â¾÷ÀÌ CAR-T ±â¼ú¿¡ ÅõÀÚÇÏ°í ¾Ï Ä¡·áÀÇ ¹Ì·¡¸¦ °³Ã´ÇÏ·Á´Â ÀÚ¼¼¸¦ °­È­ÇÏ°í ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù.

CAR-T Ä¡·áÀÌ ÁøÈ­¸¦ °è¼ÓÇÏ°í ÀÖ´Â °¡¿îµ¥, »ê¾÷Àº À¯ÀüÀÚ µµÀÔ È¿À²ÀÇ Çâ»óÀ̳ª µ¶¼º À§ÇèÀÇ °æ°¨ µî Áß¿äÇÑ °úÁ¦¿¡ Á÷¸éÇÏ°í ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº CRISPR°ú ÀÏ·ºÆ®·ÎÆ÷·¹ÀÌ¼Ç ±â¼úÀ» »ç¿ëÇÏ¿© T ¼¼Æ÷ÀÇ º¯ÇüÀ» °­È­ÇÏ´Â °ÍÀ» Àû±ØÀûÀ¸·Î ¸ð»öÇÏ°í ÀÖ´Â ¹Ý¸é, Ÿ»ç´Â CAR-T È°¼ºÀ» Á¦¾îÇÏ´Â '¿Â-¿ÀÇÁ' ½ºÀ§Ä¡¸¦ °³¹ßÇÏ°í ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇèÀº Ç÷¾×¾Ï¿¡ ºñÇØ ¿¬ÁÖÈ¿À²ÀÌ ³·´Ù´Â °ÍÀ» º¸¿©ÁֹǷΠ°íÇü¾Ï Ä¡·á°¡ ÃÖ´ë Àå¾Ö¹° Áß ÇϳªÀÓ¿¡ º¯ÇÔÀÌ ¾ø½À´Ï´Ù. ±× ¶§¹®¿¡ °íÇü¾Ï ƯÀÌÀû Ç׿øÀ» µ¿Á¤ÇÏ°í ÀÌ·¯ÇÑ ¾Ï¿¡ ´ëÇÑ È¿´ÉÀ» ÇâÃâ½ÃÅ°´Â µ¥ ÁÖ¾ÈÀ» µÎ°í ÀÖ½À´Ï´Ù.

ÇöÀç ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇèÀÇ 75% °¡±îÀÌ¿Í Ãâ½Ã°¡ ³¡³­ ¸ðµç CAR-T Ä¡·áÀº ÀÚ°¡(ȯÀÚ À¯·¡) ¼¼Æ÷¿¡ ÀÇÁ¸ÇÏ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ´ÙÀ½ ȹ±âÀûÀΠȹ±âÀûÀÎ CAR-T Ä¡·á¹ýÀº Á¦Á¶ÀÇ °£¼ÒÈ­, ºñ¿ë Àý°¨, ȯÀÚ Á¢±Ù¼ºÀ» È®´ëÇÒ ¼ö ÀÖ´Â ±â¼ºÇ° ¼Ö·ç¼ÇÀÔ´Ï´Ù.

¼¼°è CAR-T ¼¼Æ÷ Ä¡·á ½ÃÀå

CAR-T ¼¼Æ÷ Ä¡·á ½ÃÀåÀº Ãʱ⠽ÇÇè Ä¡·á¿¡¼­ ¼ö½Ê¾ï ´Þ·¯ ±Ô¸ðÀÇ »ê¾÷À¸·Î ¼ºÀåÇÏ¿© ¼¼°èÀûÀÎ È®»êÀ» º¸ÀÌ°í ÀÖ½À´Ï´Ù. Ç÷¾×¾ÏÀÇ Ãʱ⠼º°øÀº º¸´Ù ±¤¹üÀ§ÇÑ ÀÀ¿ëÀ» À§ÇÑ ±æÀ» ¿­°í ½ºÅ¸Æ®¾÷¿¡¼­ ¼±µµÀûÀÎ »ý¸í°øÇÐ ±â¾÷¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ±â¾÷µéÀÌ ÀÌ ºÐ¾ß¸¦ È®´ëÇϱâ À§ÇØ ³ë·ÂÇÏ°í ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀÌ ÁøÇàµÇ°í Àֱ⠶§¹®¿¡ CAR-T Ä¡·áÀÇ Àå·¡´Â ¼¼°èÀÇ ¾Ï Ä¡·á¿¡ Çõ¸íÀ» °¡Á®¿À´Â Çì¾Æ¸± ¼ö ¾ø´Â °¡´É¼ºÀ» Áö´Ï°í ÀÖ½À´Ï´Ù.

´Ù·ç´Â ±â¾÷°ú Á¶Á÷

  • 2seventy bio
  • Abintus Bio, Inc.
  • AffyImmune Therapeutics, Inc.
  • Aleta BioTherapeutics
  • Allogene Therapeutics
  • Anixa Biosciences, Inc.
  • Arbele, Ltd.
  • Arcellx
  • Atara Biotherapeutics
  • Aurora BioPharma
  • Autolus Therapeutics plc
  • AvenCell Europe GmbH
  • Beam Therapeutics, Inc.
  • Bellicum Pharmaceuticals
  • BioNTech
  • Biosceptre
  • Bluebird bio
  • Bristol Myers Squibb/Celgene Corporation
  • Cabaletta Bio
  • Carina Biotech
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • CARTherics Pty Ltd.
  • CASI Pharmaceuticals
  • Cellectis
  • CellGenix(Owned by Sartorius)
  • Celularity, Inc.
  • Celyad Oncology
  • CRISPR Therapeutics
  • Curocell, Inc.
  • DiaCarta
  • Elicera Therapeutics AB
  • EXUMA Biotech
  • Fate Therapeutics
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Gracell Biotechnologies
  • IASO Biotherapeutics
  • ImmPACT Bio
  • Immuneel Therapeutics, Pvt., Ltd.
  • ImmunoACT
  • Interius BioTherapeutics
  • Juventas Cell Therapy
  • JW Therapeutics
  • Kite Pharma(Gilead)
  • Kyverna Therapeutics
  • Legend Biotech
  • Leucid Bio
  • Lonza
  • Luminary Therapeutics, Inc.
  • Lyell Immunopharma, Inc.
  • March Biosciences
  • MaxCyte, Inc.
  • Miltenyi Biotec
  • Minerva Biotechnologies Corporation
  • Mustang Bio
  • Noile-Immune Biotech
  • Novartis AG
  • Oncternal Therapeutics
  • Oxford Biomedica plc
  • PeproMene Bio, Inc.
  • Poseida Therapeutics, Inc.
  • Precigen, Inc.
  • Prescient Therapeutics
  • ProMab Biotechnologies, Inc.
  • Sartorius
  • SOTIO Biotech BV
  • Syngene International, Ltd.
  • Synthekine
  • T-CURX
  • TC BioPharm
  • Umoja Biopharma
  • University of Pennsylvania
  • ViTToria Biotherapeutics
  • Vor Biopharma
  • Wugen
  • WuXi Advanced Therapies
  • Xenetic Biosciences
  • Xyphos Biosciences, Inc.
  • ±âŸ ´Ù¼ö

¸ñÂ÷

Á¦1Àå º¸°í¼­ °³¿ä

Á¦2Àå CAR-T ¼¼Æ÷ Ä¡·á: ±â¼ú °³¹ß

Á¦3Àå ¹Ì·¡ÀÇ CAR-T Ä¡·á¿¡ ´ëÇÑ Àü·«

Á¦4Àå CAR-TÀÇ °³¹ß¿¡ À־ ÁÖ¿äÇÑ »ç°Ç(1989-2024³â)

Á¦5Àå CAR-T Ç¥Àû Ç׿ø

Á¦6Àå CAR-T ¼¼Æ÷ÀÇ ½ºÄÉÀÏ·¯ºí Á¦Á¶

Á¦7Àå CAR-T ƯÇã Á¤¼¼

Á¦8Àå CAR-T ÀÓ»ó½ÃÇè »óȲ

Á¦9Àå PUBMED.GOV¿¡¼­ °ø°³µÈ CAR-T Çмú³í¹®

Á¦10Àå CAR-TÀÇ ÀÚ±Ý Á¶´Þ »óȲ

Á¦11Àå CAR-T ¼¼Æ÷Ä¡·áÀÇ ºñ¿ë¡¤»óȯ

Á¦12Àå CAR-TÀÇ ´ë»óÀÌ µÇ´Â Ç÷¾×¾Ï

Á¦13Àå ½ÃÀå ºÐ¼®

Á¦14Àå CAR-T ±â¾÷ : °³¿ä

´ÙÀ̾î±×·¥ »öÀÎ

Å×ÀÌºí »öÀÎ

KTH 25.03.04
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

AR-T cell therapy is a groundbreaking advancement in cancer treatment, offering remarkable promise for patients. This form of immunotherapy harnesses the power of the body's own immune cells, modifying them in a laboratory to enhance their ability to recognize and destroy cancer cells. Once infused back into the patient, these engineered cells multiply and persist in the body as "living drugs," continually working to fight the disease.

T-cells, a crucial component of the immune system, form the foundation of CAR-T therapy. These immune workhorses play a key role in directing immune responses and eliminating infected or abnormal cells. In CAR-T cell therapy, a patient's blood is drawn, and T-cells are separated out. Scientists then use a disarmed virus to genetically engineer these cells to express chimeric antigen receptors (CARs) on their surface. These CARs enable the T-cells to specifically target antigens found on cancer cells, leading to their destruction upon infusion back into the patient.

Global Regulatory Approvals

Since 2017, 13 CAR-T cell therapies have reached commercialization across multiple healthcare markets. Seven therapies have been approved by the U.S. FDA, after which approvals for them were issued in other major healthcare markets as well. These therapies include:

  •  
  • 1. Kymriah (tisagenlecleucel)
  • 2. Yescarta (axicabtagene ciloleucel)
  • 3. Tecartus (brexucabtagene autoleucel)
  • 4. Breyanzi (lisocabtagene maraleucel)
  •  
  • 5. Abecma (idecabtagene vicleucel)
  • 6. Carvykti (ciltacabtagene autoleucel)
  • 7. Aucatzyl (obecabtagene autoleucel)

Beyond the U.S., four CAR-T therapies-Relma-cel, Fucaso, Yuanruida, and Zever-cel-have been approved by China's National Medical Products Administration (NMPA). Additionally, two therapies, NexCAR19 and Qartemi, have received approval from India's Central Drugs Standard Control Organisation (CDSCO).

Market Expansion and Industry Growth

These regulatory approvals mark a major milestone, solidifying the CAR-T market as a dominant force in biotech. Mergers and acquisitions have been particularly aggressive, demonstrating strong investor confidence. Celgene's acquisition of Juno Therapeutics for $9 billion underscored the industry's potential, followed by Bristol-Myers Squibb (BMS) acquiring Celgene for $74 billion. Another significant move was Gilead's acquisition of Kite Pharma for $11.9 billion, further strengthening its position in the space. Additionally, Astellas Pharma expanded its portfolio by purchasing Xyphos Biosciences for $665 million. These transactions highlight the increasing commitment from major pharmaceutical companies to invest in CAR-T technologies and shape the future of cancer treatment.

As CAR-T therapy continues to evolve, the industry faces key challenges, including improving gene-transfer efficiency and mitigating toxicity risks. Researchers are actively exploring CRISPR and electroporation technologies to enhance T-cell modification, while others develop "on-off" switches to regulate CAR-T activity.

One of the biggest hurdles remains the treatment of solid tumors, as clinical trials have shown lower response rates compared to blood cancers. Thus, a major focus is on identifying solid tumor-specific antigens to improve efficacy in these cancers.

Currently, nearly 75% of ongoing clinical trials and all marketed CAR-T therapies rely on autologous (patient-derived) cells. However, the next breakthrough lies in allogeneic CAR-T therapies-off-the-shelf solutions that could streamline manufacturing, reduce costs, and expand patient accessibility.

Global CAR-T Cell Therapy Market

The CAR-T cell therapy market has grown from early experimental treatments to a multi-billion-dollar industry with global reach. Early successes in blood cancers have paved the way for broader applications, with companies ranging from startups to biotech giants working to expand the field. As innovation continues, the future of CAR-T therapy holds immense potential to revolutionize cancer treatment worldwide.

This report aims to provide readers with the following insights:

Key Questions Answered in This Report:

This global strategic report will position you to:

With the competitive nature of this global market, you don't have the time to do the research. Claim this report to become immediately informed, without missing critical opportunities.

Companies and Organizations Mentioned:

  • 2seventy bio
  • Abintus Bio, Inc.
  • AffyImmune Therapeutics, Inc.
  • Aleta BioTherapeutics
  • Allogene Therapeutics
  • Anixa Biosciences, Inc.
  • Arbele, Ltd.
  • Arcellx
  • Atara Biotherapeutics
  • Aurora BioPharma
  • Autolus Therapeutics plc
  • AvenCell Europe GmbH
  • Beam Therapeutics, Inc.
  • Bellicum Pharmaceuticals
  • BioNTech
  • Biosceptre
  • Bluebird bio
  • Bristol Myers Squibb/Celgene Corporation
  • Cabaletta Bio
  • Carina Biotech
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • CARTherics Pty Ltd.
  • CASI Pharmaceuticals
  • Cellectis
  • CellGenix (Owned by Sartorius)
  • Celularity, Inc.
  • Celyad Oncology
  • CRISPR Therapeutics
  • Curocell, Inc.
  • DiaCarta
  • Elicera Therapeutics AB
  • EXUMA Biotech
  • Fate Therapeutics
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Gracell Biotechnologies
  • IASO Biotherapeutics
  • ImmPACT Bio
  • Immuneel Therapeutics, Pvt., Ltd.
  • ImmunoACT
  • Interius BioTherapeutics
  • Juventas Cell Therapy
  • JW Therapeutics
  • Kite Pharma (Gilead)
  • Kyverna Therapeutics
  • Legend Biotech
  • Leucid Bio
  • Lonza
  • Luminary Therapeutics, Inc.
  • Lyell Immunopharma, Inc.
  • March Biosciences
  • MaxCyte, Inc.
  • Miltenyi Biotec
  • Minerva Biotechnologies Corporation
  • Mustang Bio
  • Noile-Immune Biotech
  • Novartis AG
  • Oncternal Therapeutics
  • Oxford Biomedica plc
  • PeproMene Bio, Inc.
  • Poseida Therapeutics, Inc.
  • Precigen, Inc.
  • Prescient Therapeutics
  • ProMab Biotechnologies, Inc.
  • Sartorius
  • SOTIO Biotech BV
  • Syngene International, Ltd.
  • Synthekine
  • T-CURX
  • TC BioPharm
  • Umoja Biopharma
  • University of Pennsylvania
  • ViTToria Biotherapeutics
  • Vor Biopharma
  • Wugen
  • WuXi Advanced Therapies
  • Xenetic Biosciences
  • Xyphos Biosciences, Inc.
  • And Many More

TABLE OF CONTENTS

1. REPORT OVERVIEW

2. CAR-T CELL THERAPY: TECHNOLOGY DEVELOPMENT

3. STRATEGIES FOR FUTURE CAR-T THERAPIES

4. MAJOR EVENTS DURING THE DEVELOPMENT OF CAR-T, 1989-2024

5. CAR-T TARGETED ANTIGENS

6. SCALABLE MANUFACTURING OF CAR-T CELLS

7. CAR-T PATENT LANDSCAPE

8. CAR-T CLINICAL TRIAL LANDSCAPE

9. PUBLISHED CAR-T SCIENTIFIC PAPERS IN PUBMED.GOV

10. CAR-T FUNDING LANDSCAPE

11. COST OF CAR-T CELL THERAPY & REIMBURSEMENT

12. BLOOD CANCERS ADDRESSED BY CAR-T

13. MARKET ANALYSIS

14. CAR-T COMPNIES: AN OVERVIEW

INDEX OF FIGURES

INDEX OF TABLES

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â